We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| LumiraDx Ltd | NASDAQ:LMDX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.016 | 0.014 | 0.0146 | 0 | 01:00:00 |
From May 2021 to May 2024
By Chris Wack
LumiraDx Ltd. shares were up 13%, to $8.70, after the company said it has submitted the LumiraDx SARS-CoV-2 & Flu A/B Test to the U.S. Food and Drug Administration for Emergency Use Authorization.
The company said the microfluidic immunofluorescence assay can quickly verify infection for patients suspected of flu and/or Covid-19 to aid diagnosis and clinical decision making.
The LumiraDx SARS-CoV-2 & Flu A/B Test is a rapid microfluidic immunofluorescence assay intended for the simultaneous detection of SARS-CoV-2, Influenza A, and Influenza B viral antigen direct from self or clinician collected nasal swab specimens from individuals suspected of viral infection consistent with Covid-19 by their healthcare provider within the first 12 days of the onset of symptoms.
The company currently has five tests in the market globally, and an additional 10 tests scheduled for regulatory submission or clearance by the end of 2022, including tests for troponin and congestive heart failure.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 15, 2021 09:31 ET (13:31 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year LumiraDx Chart |
1 Month LumiraDx Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
